*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
Despite the threat of a veto by President Bush, the U.S. Senate voted yesterday to loosen restrictions on federally funded human embryonic stem cell research. The Senate’s move was the latest salvo in the ongoing political battle that pits those supporting the use of government money for such research against those who do not.
This week's podcast interviewee, William Caldwell, the CEO of Advanced Cell Technology, runs a company navigating its way through this often controversial issue. Mr. Caldwell discusses how the firm is applying human embryonic stem (ES) cell technology in the field of regenerative medicine with the goal of bringing effective, patient-specific therapies to the bedside. He talks about the main challenges of translating human ES cell and nuclear transfer technology into novel therapeutic products and identifies what will be the probable first medical applications of human ES cells. Mr. Caldwell also explains why human ES cells, adult stem cells, and cord blood stem cells all need to be explored as potential therapeutics rather than as either/or propositions.
Be sure to listen to this important and very timely podcast then return the the blog and give your thoughts on the following question:
Should proponents of human embryonic stem cell research try to change the minds of people who consider an early-stage human blastula an actual person, or just focus their efforts on strengthening support for this research wherever it can be found?
Mr. William Caldwell serves as Chairman and Chief Executive Officer of the Company and has a 30-year management career working with emerging technologies and restructuring distressed corporate environments. During his career, he has served in senior executive positions both in marketing and finance. He has worked with Booz Allen and Hamilton; the Flying Tiger Line Inc.; Van Vorst Industries; and Kidder Peabody. He started a firm specializing in corporate financial and strategy planning, which was instrumental in restructuring over $1.0 billion of debt for over twenty companies and partnerships. He was a pioneer in the satellite radio auctions as president of Digital Satellite Broadcasting Corporation; assisted in the financing, and became president and ultimately CEO in the restructuring of CAIS Internet. He has advised corporations, both public and private, in technology, telecommunications, retailing, real estate, hospitality, publishing, and transportation. He received his B.A. degree from the University of Southern California and was a Multinational Enterprise Fellow at the Wharton Graduate School of Finance. He serves as a director of Lee Pharmaceuticals (LPHM.PK) and King Koil Franchising Corp.